GlassScriptPhysician profile
Christopher Hindelang
NPI 1841384070
$5,897.92
in general payments reported to CMS, 2019-2025
43 companies · $1,012 in 2025
The $1,012 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,377 · 2022: $2,213 · 2023: $504 · 2024: $792 · 2025: $1,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,167 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,167.27 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $953.46 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $493.09 | 2021-2025 | |
| Amgen INC. | $368.33 | 2021-2025 | Tavneos |
| Janssen Biotech, INC. | $359.48 | 2021-2025 | Tremfya |
| Lilly USA, LLC | $345.18 | 2021-2025 | Mounjaro, Jardiance |
| Ani Pharmaceuticals, INC. | $323.34 | 2022-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $281.83 | 2021-2022 | |
| Allergan, INC. | $280.64 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $237.16 | 2025 | Tarpeyo |
| Ucb, INC. | $230.81 | 2021-2025 | Bimzelx |
| Leo Pharma INC. | $204.14 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $176.21 | 2021-2022 | |
| Incyte Corporation | $174.22 | 2021-2022 | |
| Pfizer INC. | $147.22 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $107.93 | 2025 | Acthar |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hindelang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.